Mannatech’s plant-based vitamins
This article was originally published in The Tan Sheet
Executive SummaryThe Coppell, Texas-based nutritionals firm announces plans for a fourth-quarter launch of PhytoMatrix - a fully standardized and plant-based vitamin, mineral and phytochemical supplement. The product "will not contain any synthetic or chemically derived active ingredients;" rather, PhytoMatrix supplements will be manufactured with "vitamins, minerals and phytochemicals that have been absorbed by a plant's roots and stored in its tissue," providing all-natural ingredients, Mannatech states. The company has acquired exclusivity to Integrated Biopharma's "patented, hydroponic cultivation technology" that produces plants with increased quantities of minerals. A daily serving provides consumers with a "substantial portion of the Recommended Daily Allowance of vitamins and minerals as well as powerful plant-derived phytochemicals," according to Mannatech...
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2019.